ACETAMINOPHEN | N206610 | RISING PHARMA HOLDING INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 2 | Active | University of Miami | 310 | 2020-02-11 → 2027-02-01 | |
| Phase 1 | Active | Baylor College of Medicine | 68 | 2009-04 → 2031-04 | |
| Phase 4 | Active | University of California, Davis | 60 | 2021-01-20 → 2026-06-24 | |
| Phase 3 | Active | Hoffmann-La Roche | 271 | 2020-08-10 → 2031-03-02 | |
| Phase 3 | Active | Sanofi | 337 | 2020-06-16 → 2033-10-21 | |
| Phase 2 | Active | National Cancer Institute (NCI) | 69 | 2010-07-01 → 2027-12-31 | |
| Phase 1 | Active | National Cancer Institute (NCI) | 18 | 2019-10-03 → 2029-06-30 | |
| Phase 3 | Recruiting | St. Louis University | 60 | 2019-02-20 → 2027-03-31 | |
| Phase 4 | Recruiting | University of California, Los Angeles | 90 | 2019-02-26 → 2027-12-20 | |
| Phase 4 | Recruiting | Sanford Health | 148 | 2018-10-29 → 2028-01 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
15 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Jan 19, 2021 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.